Dako and Quintiles form alliance to speed development of personalized medicine

02-Nov-2010 - Denmark

Dako and Quintiles announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca in the development of one of its leading oncology compounds.

"Quintiles and Dako share the same goals for speed, quality and efficiency," said Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories. "By pairing our core competencies in translational medicine, biomarker discovery and managing clinical trials with Dako's expertise in companion diagnostics, we can help physician investigators select the right patients for the right clinical trials, thereby accelerating the development of personalized oncology therapies for our customers in the New Health landscape."

As part of the alliance, Dako will develop cancer diagnostic tests, and Quintiles will conduct the tests as part of the clinical validation. Both Dako and Quintiles will continue to work independently with biopharmaceutical companies and service providers in the industry.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content